Bioidentical Hormones - U.S. Senate Special Committee on Aging
Bioidentical Hormones - U.S. Senate Special Committee on Aging
Bioidentical Hormones - U.S. Senate Special Committee on Aging
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
245<br />
This report addresses the state laws and regulati<strong>on</strong>s related to the five protecti<strong>on</strong>s<br />
set forth above. 2 As described more fully below, these laws and regulati<strong>on</strong>s do not<br />
provide the protecti<strong>on</strong>s offered to patients under the current or proposed provisi<strong>on</strong>s of the<br />
FDCA.<br />
FINDINGS<br />
1. Disclosure that a Product Is Compounded<br />
* Only six states require that a pharmacy disclose to the patient that the drug being<br />
dispensed is a compounded drug.<br />
In Ariz<strong>on</strong>a, pharmacists must include <strong>on</strong> the label: "a statement, symbol, designati<strong>on</strong>, or<br />
abbreviati<strong>on</strong> that the pharmaceutical product is a compounded pharmaceutical product."<br />
Ariz. Admin. Code § R4-23-410(l)(4) (2007). In Colorado, the pharmacist must include<br />
the following statement <strong>on</strong> the label of all compounded drugs: "This product was<br />
compounded by the pharmacy." 3 Colo. Code Regs. § 719- 1 (2007). In Iowa, when a<br />
compounded product is to be dispensed in place of a commercially available product, the<br />
pharmacist must inform both the prescriber and the patient that the product will be<br />
compounded. See Iowa Admin. Code r. 657-20.3(1) (2007). In Oklahoma, the<br />
pharmacist must include <strong>on</strong> the label "an appropriate designati<strong>on</strong> that this is a<br />
compounded prescripti<strong>on</strong>." Okla. Admin. Code § 535:16-10-9 (2007). In Alaska, the<br />
patient must be made aware that the compounded product will be prepared by the<br />
pharmacist. Alaska Divisi<strong>on</strong> of Corporati<strong>on</strong>s, Business and Professi<strong>on</strong>al Licensing,<br />
Pharmacy Statutes and Regulati<strong>on</strong>s, at Appendix C (2007). In Washingt<strong>on</strong>, a<br />
entrnoumded {Lg c<strong>on</strong>, be substiuted for a cor -crcially available duuig Oity witl dilc<br />
written authorizati<strong>on</strong> of both the patient and the prescriber. Wash. Admin. Code § 246-<br />
878-020(1).<br />
2. Active Ingredients Used in Compounded Drugs<br />
* The vast majority of states do not address the quality or types of active ingredients<br />
compounding pharmacists may use.<br />
* Of the fiteen states that address the issue, eleven permit the pharmacist to rely <strong>on</strong><br />
"professi<strong>on</strong>al<br />
judgment."<br />
See, e.g., Alaska Divisi<strong>on</strong> of Corporati<strong>on</strong>s, Business and Professi<strong>on</strong>al Licensure,<br />
Pharmacy Statutes and Regulati<strong>on</strong>s, at Appendix C (providing that "a pharmacist shall<br />
use the pharmacist's professi<strong>on</strong>al judgment to receive, store and use drug substances for<br />
compounding prescripti<strong>on</strong>s not foundin official compendia").<br />
2 This report reflects research performed by examining state statutes and regulati<strong>on</strong>s relating to the<br />
practice of pharmacy. Our research included searches in various databases (including WESTLAW and<br />
LEXIS), as well as review of statutory codes, administrative codes and other compilati<strong>on</strong>s published by<br />
various states and available <strong>on</strong>line.